{"schema_version":"1","generated_at":"2026-11-22T01:59:46.230Z","data_as_of":null,"url":"https://www.findmykol.com/kol/mark-scarupa","json_url":"https://www.findmykol.com/kol/mark-scarupa/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"mark-scarupa","name":"Mark Scarupa","credential":"MD","specialty":"Allergy & Immunology","specialty_raw":"Allergy & Immunology","therapeutic_area":"Rheumatology/Immunology","therapeutic_areas":["Rheumatology/Immunology"],"institution":"Institute for Asthma and Allergy","institution_url":"https://www.findmykol.com/institution/institute-for-asthma-and-allergy","city":"Wheaton","state":"MD","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"on_file":["npi","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Mark Scarupa is a Rheumatology/Immunology physician affiliated with Institute for Asthma and Allergy. OpenAlex indexes 35 publications with 326 citations (h-index 8).","overview":null,"focus":{"indications":[],"research_topics":["Rheumatology/Immunology"]},"scholarship":{"works_count":35,"cited_by_count":326,"h_index":8,"latest_activity_year":2026,"emerging":true,"source":"works"},"payments":{"company_count":42,"program_years":{"first":2021,"last":null},"rows_total":138,"shown":3,"withheld":135,"rows":[{"payer":"Genentech USA, Inc.","program_year":2025,"amount_usd":37261.13,"payment_count":42},{"payer":"Blueprint Medicines Corporation","program_year":2025,"amount_usd":33743.79,"payment_count":32},{"payer":"GSK","program_year":2025,"amount_usd":22842.3,"payment_count":7}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":5,"areas_shown":3,"areas":[{"area":"Respiratory","share_pct":56.3,"classes_total":4,"classes":[{"class":"Anti-IgE","setting":"administered","share_pct":54.9,"drugs":[{"name":"Omalizumab","share_pct":100}],"max_beneficiaries":30},{"class":"Histamine-1 Receptor Antagonist","setting":"prescribed","share_pct":0.6,"drugs":[{"name":"Azelastine-Fluticasone","share_pct":54},{"name":"Azelastine Hcl","share_pct":46}],"max_beneficiaries":15}]},{"area":"Anti-infectives","share_pct":42.9,"classes_total":3,"classes":[{"class":"Human Immunoglobulin G","setting":"administered","share_pct":42.7,"drugs":[{"name":"Immune globulin","share_pct":100}],"max_beneficiaries":16},{"class":"Tetracycline-class Drug","setting":"prescribed","share_pct":0.1,"drugs":[{"name":"Doxycycline Hyclate","share_pct":100}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":0.4,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":0.4,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":30}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":35,"shown":5,"withheld":30,"matched_by":"OpenAlex author record","recent":[{"title":"Bradykinin Quantification To Diagnose and Monitor Normal-C1 Esterase Inhibitor Angioedema","year":2026,"journal":"Journal of Allergy and Clinical Immunology","source_url":"https://doi.org/10.1016/j.jaci.2025.12.094","status":"verified"},{"title":"Correction to: A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency","year":2026,"journal":"Journal of Clinical Immunology","source_url":"https://doi.org/10.1007/s10875-026-01983-6","status":"verified"},{"title":"Ex vivo bradykinin as a functional biomarker for angioedema with normal C1-inhibitor","year":2026,"journal":"Journal of Allergy and Clinical Immunology Global","source_url":"https://doi.org/10.1016/j.jacig.2026.100735","status":"verified"},{"title":"Bradykinin measurement by liquid chromatography tandem mass spectrometry in subjects with hereditary angioedema enhanced by cold activation","year":2025,"journal":"Journal of Allergy and Clinical Immunology Global","source_url":"https://doi.org/10.1016/j.jacig.2025.100505","status":"verified"},{"title":"A Multicentric Clinical Study to Evaluate Pharmacokinetics, Efficacy, and Safety of Immune Globulin Subcutaneous 20% Weekly/Biweekly Dosing in Treatment-Experienced Patients and Loading/Weekly Maintenance Dosing in Treatment-Naïve Patients with Primary Immunodeficiency","year":2025,"journal":"Journal of Clinical Immunology","source_url":"https://doi.org/10.1007/s10875-025-01952-5","status":"verified"}],"source":"works"},"similar":[{"name":"Michael Kaliner","slug":"michael-kaliner","institution":"Institute for Asthma and Allergy","specialty":"Allergy & Immunology","url":"https://www.findmykol.com/kol/michael-kaliner","json_url":"https://www.findmykol.com/kol/michael-kaliner/profile.json"},{"name":"Martha V. White","slug":"martha-white","institution":"Institute for Asthma and Allergy","url":"https://www.findmykol.com/kol/martha-white","json_url":"https://www.findmykol.com/kol/martha-white/profile.json"},{"name":"Huamin Li","slug":"huamin-li","institution":"Institute for Asthma and Allergy","specialty":"Allergy","url":"https://www.findmykol.com/kol/huamin-li","json_url":"https://www.findmykol.com/kol/huamin-li/profile.json"},{"name":"David Felson","slug":"david-felson","institution":"Boston University","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/david-felson","json_url":"https://www.findmykol.com/kol/david-felson/profile.json"},{"name":"Marc Hochberg","slug":"marc-hochberg","institution":"University of Maryland School of Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/marc-hochberg","json_url":"https://www.findmykol.com/kol/marc-hochberg/profile.json"},{"name":"Philip Mease","slug":"philip-mease","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/philip-mease","json_url":"https://www.findmykol.com/kol/philip-mease/profile.json"},{"name":"Michelle Petri","slug":"michelle-petri","institution":"Johns Hopkins University School of Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/michelle-petri","json_url":"https://www.findmykol.com/kol/michelle-petri/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":135,"publications":30}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}